Evofem Biosciences Receivables

Evofem Biosciences (EVFM) currently reports a receivables of $560K as of March 2026. That compares with $1.1M in the prior-year period — down 51.3% year over year. Use the charts on this page to explore Evofem Biosciences's receivables history and peer comparisons.

Evofem Biosciences's receivables decreased from $1.1M to $560K — a 51.3% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Evofem Biosciences reported $560K in receivables as of March 2026. That compares with $1.1M in the prior-year period — down 51.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $560K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Evofem Biosciences, and consider following EVFM for alerts when major investors trade the stock.

Evofem Biosciences is classified in the Healthcare sector. On receivables, it currently shows $560K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EVFM with unrelated industries.